🦠 Welcome back to the Pulse 🦠
This week we look at some amazing developments in the world of oncology and cancer treatment!
🎀 How groundbreaking research could lead to new treatments for tripple negative breast cancer.
💊 How an already established drug could lead to more blood cancer patients receiving treatment from partially matched donors.
🎓 A huge congratulations to Prof Dean A. Fennell for being elected to the prestigious Fellowship of the Academy of Medical Sciences.
For more insights into the world of Life Sciences and to see more of our video content, check out the comments below!
Hi and welcome to The Pulse, your one stop shop for everything life sciences news. As always, I'm your host, Erin Bynon and I am joined again by Emily Davis. Today we're looking at everything oncology, cancer and cancer treatment is something very close to our hearts here at me and we just wanted to shine some light on some amazing developments that happened over the past few months. First stop today in a groundbreaking study. Scientists have devised a novel approach to combat triple negative breast cancer by leveraging the cancer cells own vulnerabilities. The research, published in Clinical Cancer Research by a team from Kings College London and funded by Breast Cancer Now and vales a new strategy they could revolutionize treatment for this hard to treat cancer. Triple negative breast cancer constitutes 15% of all breast cancer cases and is known for being particularly aggressive and resistant to conventional treatments like chemotherapy. It often affects younger women and has a lower survival rate. Current treatment methods surgery, chemotherapy and radiotherapy. Frequently failed to prevent the cancer from returning and spreading. The researchers conducted an extensive analysis of over 6000 breast cancer samples to understand the unique properties of triple negative breast cancer cells. Their goal was to identify markers and mechanisms that contribute to the cancers aggressive drug resistant nature. They discovered that triple negative breast cancer cells often expressed their cancer cell surface marker EGFR. And how about oncogenic molecules which drive cell division and proliferation. But cycling these makes the team developed a novel treatment and antibody drug conjugate this conjugate. Things achievement Selective antibody targeting EGFR with the CDK blocking drug. The result is a highly specific therapy that directs the toxic drug to the cancer cells, potentially allowing for lower doses and reducing side effects for patients. What further studies are required? This innovative therapy represents a significant step forward in the fight against triple negative breast cancer. The researchers hope that their findings will pave the way for new, effective treatments tailored to specific needs of patients with the challenging form of cancer. Our next story focuses on a new treatment strategy using an already established. Cyclophosphamide, which is showing promise for enabling more patients with high risk blood cancers to receive life saving stem cell transplants from unrelated, partially matched donors. This approach research by scientists at Sylvester Comprehensive Cancer Centre at the University of Miami Miller School of Medicine and their colleagues could significantly broaden the donor pool, particularly benefiting underrepresented racial and ethnic groups. The results of this study are said to be presented at the annual meeting of American Society of Clinical Oncology and the European Hematology Association. The new method? Involves administering cyclophosphamide several days post transplantation, leading to outcomes that are comparable to those of fully matched donors. This discovery could be transformative for patients who struggles to find suitable donors through traditional registries. Finding a compatible donor has historically been a significant challenge for blood cancer patients requiring bone marrow or blood stem cell transplants. The National Marrow Donor Programmes Registry has over 40 million potential donors, yet matches are often elusive, especially for Hispanic and Black patients. Earlier, about half of Hispanic and a quarter of black patients. Mindfully much donor compared to over 70% of white patients. Cyclophosphamide and older drug is being repurposed to facilitate successful transplants from partially matched donors and ministered several days after transplantation. Cyclophosphamide helps mitigate grants versus host disease, a serious condition where the transplant attacks the patient's body. This strategy has shown high success rates in patients receiving blood stem cells from unrelated partially matched donors. Preliminary data from the study, which involves 70 adult patients with advanced blood cancers, show a high survival rate of 79. Percent at this rate is on par with outcomes from fully matched donors. Additionally, 51% of patients were free of GVHD and had not relapsed after one year. These findings are particularly noteworthy given the highest nature of the patient group and the average age of 65. The study also highlights the potential for overcoming the genetic diversity challenges in HLA. Matching donors with match levels from 4 out of eight to seven out of eight on the HLA scale can be used, significantly expanding the pool of eligible donors at match levels of five out of eight and above nearly all individuals. Comes out verse racial and ethnic backgrounds are expected to find a donor. New approach is already being implemented at Sylvester and other medical centres, enabling more patients to find suitable donors and received treatment. This method allows for the selection of better donors, such as younger individuals with healthier graphs and hunting the overall success rate of these transplants. The research represents a significant advancement in making stem cell transplants more accessible and effective for high risk blood concentrations, particularly those from underrepresented backgrounds. And finally, Professor Dean Fenella, leading cancer specialist at the University of Leicester, has been recognized for his ground breaking research into. Like the metaphor, the OMA by being elected into the prestigious Fellowship of the Academy of Medical Sciences. Professor Fennell, who holds the position of Chair of Thoracic Medical Oncology, has devoted his career to studying MPM, rare aggressive form of lung cancer. His journey began in the early 2000s when, as a junior doctor in London, he and a colleague developed a novel strategy to combat mesothelioma by depriving tumours of their nutrient supply. This innovative approach has led to significant advancements in treatment options for this devastating disease. The research spearheaded by Professor. Have culminated in a breakthrough clinical trial that launched this year. Patients in Leicester have been on receiving a new combination chemotherapy treatment based on her study. The trial results have been promising, showing a significant increase in survival rates for those affected with MPM, which previously had very limited effective treatments. In recognition of his exceptional contributions to the field, Professor Farrell has been elected to the Fellowship of the Academy of Medical Sciences. This honor is bestowed upon individuals who have made remarkable advancements in biomedical and Health Sciences achieving Great Britain research discoveries and translated these developments into tangible. Benefits for patients and society Joining the ranks of over 1400 Esteven Fellows, Professor Fenner will be part of a distinguished group that plays a crucial role in shaping the future of biomedical research and health policy in the UK and wildlife. The fellowship includes leading researchers from various sectors including the NHS, academia, industry and public service. Professor Andrew Morris, President of the Academy of Medical Sciences, welcomed the new Fellows, stating our new Fellows leads pioneering work in biomedical research and our driving remarkable improvements in healthcare. We look forward to working with them and learning from them in our quest to Foster and open and progressive research environment that improves the health of people everywhere through excellence in medical science. Professor Fennel will formally be admitted to the Academy at a ceremony on September 18th. The Academy of Medical Sciences continues to advance its mission of promoting biomedical and health research and translating scientific discoveries into societal benefits through the efforts of the selected fellows. And that's all from the falls this week. But if you want to catch more insights, head over to our YouTube channel, which is linked to below or. Head over to the Media Hub at www.peoplewithchemistry. com/media Dash Hub. See you next time.
April is Esophageal Cancer Awareness Month. According to the American Cancer Society, about 22,000 new cases of esophageal cancer will be diagnosed in the United States this year. We’ve asked Arizona Oncology medical oncologist and hematologist, Dr. Suresh Mukkamala, to answer a few questions about this relatively rare cancer that affects more men than women. https://lnkd.in/eBvDPazg#esophagealcancerawareness#esophagealcancer#cancerprevention#cancerblog
Read the new issue of Cancer Today, available now with stories on peripheral neuropathy, stress and cancer, advances in metastatic breast cancer, and more. https://bit.ly/48thUlp
To make the biggest impact with our lung cancer research, we concentrate our efforts on five areas of focus. These are the foundation of what we do, how we approach investigator-initiated clinical trials, and how we strive to make lung cancer a survivable disease. Our studies often lead to publications in the world’s most prestigious peer-reviewed oncology journals. Follow us to learn more! #lungcancer#cancerresearch#lungcancerawareness
Ying Liu, MD, MPH, of Memorial Sloan Kettering Cancer Center, was awarded the FWC 2023-2024 Wilma Williams Education and Clinical Research Grant for Endometrial Cancer at this year's Society of Gynecologic Oncology Annual Meeting.
In this interview, Dr. Liu elaborates on potential advancements in gynecologic cancer research, including her research that aims to utilize the microbiome and changes in therapies to identify women who would benefit most from additional treatments. #AAPIMonth#NationalCancerResearchMonth
🌐 In our ongoing series, we introduce the members of Indivumed’s Onco AI-Med Board. This time, we are excited to feature David Kerr, Professor of Cancer Medicine at the University of Oxford, who underscores the importance of global cooperation and tissue quality in advancing cancer treatment:
"The Onco AI-Med board is a fantastic example of what we can do with truly international cooperation. And what Indivumed have shown is how critically, utterly important the precision of tissue collection is to be able to interpret it on behalf of our cancer patients, and through that interpretation, we hope ultimately to come up with effective new drugs."
We are grateful for the invaluable contributions of these experts and appreciate the collaboration, exchange, and insights that drive precision oncology forward!
#PrecisionOncology#InternationalCooperation#CancerResearch
Exciting news for breast cancer research! A new chapter by Dr. Kamal Saini and colleagues, published by Springer Nature, explores how Artificial Intelligence (AI) can revolutionize breast cancer treatment.
The chapter dives into how AI can potentially:
• Improve early detection
• Help design more effective drugs
• Combat drug resistance, a major challenge in treatment
This research offers hope for a future where AI personalizes treatment and improves outcomes for breast cancer patients.
https://lnkd.in/ghBnPzpY#BreastCancer#AIinHealthcare#DrugDiscovery#PersonalizedMedicine
For more Life Sciences insights: https://www.peoplewithchemistry.com/media-hub/ Our YouTube channel: https://www.youtube.com/channel/UCRPGqEpU3gQOduDTACt3dcA